Trends in MDS and AML from ASH 2023

被引：0
|
作者：
Pfeilstoecker, Michael [1 ]
机构：
[1] Hanusch Hosp, Med Dept 3, H Collinstr 30, A-1140 Vienna, Austria
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2024年 / 17卷 / 03期
关键词：
Acute myeloid leukemia; Myelodysplastic neoplasms; Clonal hematopoiesis; Targeted molecular therapy; Allogeneic transplantation;
D O I：
10.1007/s12254-024-00984-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Presentations in the field of clonal myeloid diseases from the 65th American Society of Hematology conference provided insights into future therapeutic approaches especially for the subset of older patients. While new drugs and concepts for acute myeloid leukemia need further work before clinical implementation, some data on myelodysplastic neoplasms providing new treatment options for transfusion-dependent low-risk patients are already practice-changing.
引用
收藏
页码：178 / 181
页数：4
相关论文
共 50 条
  • [21] Randomized study comparing chemotherapy ±GM-CSF in high-risk MDS and AML following MDS (MDS-AML).
    Ohm, AC
    Hast, R
    Bernell, P
    Celsing, F
    Dahl, IM
    Dybedal, I
    Lindberg, G
    Linder, O
    Löfvenberg, E
    Nilsson-Ehle, H
    Samuelsson, J
    Tangen, J
    Turesson, I
    Wallvik, J
    Winquist, I
    Öberg, G
    Björkholm, M
    Hellström-Lindberg, E
    BLOOD, 2000, 96 (11) : 148A - 148A
  • [22] Animal models for AML, MDS and MPN
    Kitamura, Toshio
    JOURNAL OF GENE MEDICINE, 2014, 16 (7-8): : 197 - 197
  • [23] Categorizing Molecular Mutations in MDS and AML
    Rose, Dominic
    Haferlach, Torsten
    Kern, Wolfgang
    Haferlach, Claudia
    BLOOD, 2015, 126 (23)
  • [24] What came first: MDS or AML?
    Walter, Matthew J.
    BLOOD, 2015, 125 (09) : 1357 - 1358
  • [25] ICSH guidelines on immunophenotyping in AML and MDS
    Kern, W.
    ONKOLOGIE, 2013, 36 : 36 - 37
  • [26] CHILDHOOD MDS TREATED WITH AML REGIMENS
    HASLE, H
    KERNDRUP, G
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 1995, 40 (02): : 18 - 18
  • [27] FLOW CYTOMETRIC EVALUATION OF MDS/AML
    Kern, Wolfgang
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2014, 36 : 20 - 21
  • [28] MOLECULAR BASIS FOR AML, MDS AND MPN
    Kitamura, T.
    Nakahara, F.
    Kato, N.
    Watanabe-Okochi, N.
    Komeno, Y.
    Doki, N.
    Togami, K.
    Uchida, T.
    Kagiyama, Y.
    Inoue, D.
    Enomoto, Y.
    Oki, T.
    Harada, H.
    Chiba, S.
    Kitaura, J.
    EXPERIMENTAL HEMATOLOGY, 2010, 38 (09) : S107 - S108
  • [29] Targeting CBP/β-Catenin in MDS/AML
    Jiang, E.
    Nguyen, C.
    Kim, H. N.
    Khaled, Samer
    McDonald, Tinisha
    Marcucci, Guido
    Teo, J. L.
    Kahn, M.
    Kim, Y. M.
    ANNALS OF HEMATOLOGY, 2019, 98 : S49 - S50
  • [30] Guadecitabine for AML and MDS: hype or hope?
    Kharfan-Dabaja, Mohamed A.
    LANCET ONCOLOGY, 2015, 16 (09): : 1009 - 1011
12345